NB46 Nanobody: Preclinical Radiotheranostic Data for HER2-Positive Tumors

Lingzhou Zhao published a dataset on figshare in April 2026 detailing the development of a novel nanobody for radiotheranostics. The data likely contains results from in vitro and in vivo studies of the NB46 nanobody labeled with 68Ga and 177Lu, including affinity, biodistribution, and tumor growth inhibition metrics. The dataset is small, at 1.5 KB, and is provided in CSV format.

Use Cases

• Analyze in vitro binding affinity and specificity of the NB46 nanobody based on the described HER2 affinity tests.
• Model pharmacokinetics and biodistribution based on the described rapid blood clearance and tumor accumulation data in mice.
• Assess therapeutic efficacy and dose-response relationships based on the described tumor growth inhibition and survival extension results.
• Evaluate off-target organ toxicity based on the described kidney dose-limiting data.

Strengths

• Data is associated with a specific, novel molecular agent (NB46 nanobody) engineered with a GSC tripeptide.
• Results cover both diagnostic (68Ga) and therapeutic (177Lu) radionuclides, forming a theranostic pair.
• Preclinical evaluation includes multiple metrics: in vitro affinity, in vivo biodistribution, tumor retention, and therapy outcomes.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (1.5 KB), indicating limited scope, likely summary statistics rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Likely contains summarized results from the described preclinical laboratory study.

Freshness

Last updated 2026-04-11 02:05:56; freshness should be verified.